Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Surgical & Infection Prevention | | | | | | | | 1,139.3 |
| Medical Devices | | | | | | | 509.0 | 501.7 |
| Corporate & Other | | | | | | | | 31.1 |
| Total revenues [+] | 744.6 | 714.8 | 697.6 | 652.3 | 611.6 | 566.2 | 509.0 | 1,672.1 |
| Products | 744.6 | 714.8 | 697.6 | 652.3 | 611.6 | | | |
| Revenue growth [+] | 4.2% | 2.5% | 6.9% | 6.7% | 8.0% | 11.2% | -69.6% | -0.3% |
| Surgical & Infection Prevention | | | | | | | | -1.2% |
| Medical Devices | | | | | | | 1.5% | 0.5% |
| Corporate & Other | | | | | | | | 22.4% |
| Cost of goods sold | 380.3 | 341.5 | 295.4 | 261.4 | 274.7 | 269.0 | 251.2 | 1,123.5 |
| Gross profit | 364.3 | 373.3 | 402.2 | 390.9 | 336.9 | 297.2 | 257.8 | 548.6 |
| Gross margin | 48.9% | 52.2% | 57.7% | 59.9% | 55.1% | 52.5% | 50.6% | 32.8% |
| Selling, general and administrative | 300.3 | 332.6 | 399.1 | 340.4 | 321.7 | 346.2 | 349.7 | 424.5 |
| Research and development | 32.3 | 34.9 | 37.7 | 41.8 | 38.2 | 38.4 | 27.6 | 33.6 |
| Other operating expenses | 22.8 | 51.9 | 21.1 | 8.2 | 20.1 | 19.7 | 16.2 | -3.8 |
| EBITDA [+] | 47.2 | -3.2 | -18.8 | 34.0 | 16.4 | -41.9 | -70.3 | 179.7 |
| EBITDA growth | -1575.0% | -83.0% | -155.3% | 107.3% | -139.1% | -40.4% | -139.1% | -39.0% |
| EBITDA margin | 6.3% | -0.4% | -2.7% | 5.2% | 2.7% | -7.4% | -13.8% | 10.7% |
| Depreciation | 21.6 | 23.5 | 16.9 | 13.5 | 38.8 | 43.8 | 40.4 | 53.4 |
| EBITA | 25.6 | -26.7 | -35.7 | 20.5 | -22.4 | -85.7 | -110.7 | 126.3 |
| EBITA margin | 3.4% | -3.7% | -5.1% | 3.1% | -3.7% | -15.1% | -21.7% | 7.6% |
| Amortization of intangibles | 16.7 | 19.4 | 20.0 | 20.0 | 20.7 | 21.4 | 25.0 | 32.0 |
| EBIT [+] | 8.9 | -46.1 | -55.7 | 0.5 | -43.1 | -107.1 | -135.7 | 94.3 |
| EBIT growth | -119.3% | -17.2% | -11240.0% | -101.2% | -59.8% | -21.1% | -243.9% | -58.1% |
| EBIT margin | 1.2% | -6.4% | -8.0% | 0.1% | -7.0% | -18.9% | -26.7% | 5.6% |
| Interest expense, net [+] | 3.1 | 14.4 | 8.3 | 18.6 | 29.1 | 32.1 | 32.8 | 3.1 |
| Interest expense | 3.3 | 15.6 | 15.0 | 26.4 | 31.6 | 32.7 | 33.1 | 6.0 |
| Interest income | 0.2 | 1.2 | 6.7 | 7.8 | 2.5 | 0.6 | 0.3 | 2.9 |
| Pre-tax income | 5.8 | -60.5 | -64.0 | -18.1 | -72.2 | -139.2 | -168.5 | 91.2 |
| Income taxes | 0.6 | -33.3 | -18.1 | -9.6 | -40.1 | -55.9 | -67.3 | 64.1 |
| Tax rate | 10.3% | 55.0% | 28.3% | 53.0% | 55.5% | 40.2% | 39.9% | 70.3% |
| Earnings from continuing ops | 5.2 | -27.2 | -45.9 | -8.5 | -32.1 | -83.3 | -101.2 | 27.1 |
| Earnings from discontinued ops | | | | 0.0 | 0.0 | | | |
| Net income | 5.2 | -27.2 | -45.9 | 57.5 | 79.3 | 39.8 | -426.3 | 27.1 |
| Net margin | 0.7% | -3.8% | -6.6% | 8.8% | 13.0% | 7.0% | -83.8% | 1.6% |
| |
| Basic EPS [+] | $0.11 | ($0.57) | ($0.96) | ($0.18) | ($0.69) | ($1.79) | ($2.17) | $0.58 |
| Growth | -119.0% | -41.0% | 435.5% | -73.7% | -61.6% | -17.7% | -472.6% | -82.5% |
| Diluted EPS [+] | $0.11 | ($0.57) | ($0.96) | ($0.18) | ($0.69) | ($1.79) | ($2.17) | $0.58 |
| Growth | -118.8% | -41.0% | 435.5% | -73.7% | -61.6% | -17.7% | -472.6% | -82.5% |
| |
| Shares outstanding (basic) [+] | 48.1 | 47.8 | 47.6 | 47.2 | 46.8 | 46.6 | 46.6 | 46.5 |
| Growth | 0.6% | 0.4% | 0.8% | 0.9% | 0.4% | 0.0% | 0.2% | 0.0% |
| Shares outstanding (diluted) [+] | 48.6 | 47.8 | 47.6 | 47.2 | 46.8 | 46.6 | 46.6 | 46.5 |
| Growth | 1.7% | 0.4% | 0.8% | 0.9% | 0.4% | 0.0% | 0.2% | 0.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|